Antihistamines in Psoriasis

Swathi Shivakumar, Simon M. Mueller, Paul S. Yamauchi, Jeffrey M. Weinberg, Leon Kircik, Jacek C. Szepietowski, Mohamad Goldust

Research output: Contribution to journalArticlepeer-review


Psoriasis is polygenic, interleukin (IL)-17 and IL-23 driven chronic relapsing inflammatory multisystem disease caused by a complex interplay of endogenous and environmental factors. The most common and distressing symptom in psoriasis is itch, adding significantly to the burden of disease. Although histamine has historically not been considered a key itch mediator in psoriasis, there is some evidence from the literature that antihistamines may be effective to reduce itch in psoriasis. This review focuses on the role of antihistamines in the management of itch in psoriasis. The literature search included peer-reviewed articles published in English language (clinical trials or scientific reviews). Studies were identified by searching electronic databases (MEDLINE and PubMed) until January 2021 and by reference lists of respective articles.

Original languageEnglish
Pages (from-to)844-847
Number of pages4
JournalJournal of Drugs in Dermatology
Issue number8
StatePublished - Aug 2021


Dive into the research topics of 'Antihistamines in Psoriasis'. Together they form a unique fingerprint.

Cite this